Published in Cancer Weekly, May 15th, 2001
Authors of this new study tested TNP-470 on mice inoculated with neuroblastoma cells. Their results, reported in Clinical Cancer Research, show TNP-470 as a strong angiogenesis inhibitor when administered by continuous infusions or during intermittent dosing.
"Treatment was given as a single agent in established xenografts, 10 days after 450 mg/kg of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.